Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2022-09-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - IMU 9 pages 33.4KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification regarding the issue of unquoted equity securities (unlisted options) by Imugene Limited. It includes specifics such as the number of securities issued, issue dates, security descriptions, and compliance with ASX listing rules. The content focuses on the issuance of new securities and related regulatory disclosures rather than financial performance, management changes, or meeting results. This matches the definition of a Share Issue/Capital Change filing, which covers announcements about new share issues or capital changes. The document is substantive and not merely an announcement of a report or a certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2022-09-19 English
OGTR grants VAXINIA DIR licence allowing trial expansion 3 pages 217.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited regarding the granting of a DIR licence by the Australian Government's Office of the Gene Technology Regulator (OGTR) to expand a Phase 1 clinical trial in Australia. It is a regulatory update about a clinical trial expansion and does not contain financial statements, earnings data, or detailed management discussion. The document is relatively short (4634 characters) and serves as a formal announcement of a regulatory approval related to clinical trial operations. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is the announcement itself, not about a report release. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-09-18 English
Application for quotation of securities - IMU 8 pages 29.7KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application for quotation of securities issued by Imugene Limited. It includes information about the number and type of securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document references previous announcements (Appendix 3B) related to the securities issuance. There is no financial performance data, management discussion, or audit information. The document is an official announcement related to the listing or quotation of securities on the ASX, which corresponds to a capital or financing update rather than a full financial report or regulatory filing. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (6206 characters) is sufficient to contain substantive information about the securities quotation, not just a brief notice or report publication announcement.
2022-09-18 English
Notice Under Section 708A 1 page 158.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 19 September 2022, providing a notice under Section 708A(5) of the Corporations Act 2001. It details the issuance of 400,000,000 ordinary shares at $0.20 each without disclosure under Part 6D.2 of the Corporations Act. The content focuses on compliance statements related to the share issue and legal requirements, without any financial statements or detailed financial analysis. The document length is short (1402 characters) and it is clearly an announcement of a capital raising event rather than a full report or detailed financial disclosure. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-09-18 English
Prospectus for the issue of institutional placement options 31 pages 620.4KB
Capital/Financing Update Classification · 100% confidence The document is titled as a 'Prospectus for the issue of institutional placement options' and details the issuance of new options to acquire shares, including terms, risk factors, and financial information. It is a transaction-specific prospectus prepared under section 713 of the Corporations Act 2001 (Cth). The content focuses on the offer of new options, their terms, and related investment information, which aligns with a capital raising or financing activity. This is not a full annual or interim report, nor an earnings release or management discussion. It is a formal offer document for new securities issuance, which fits the definition of a Capital/Financing Update (CAP). The document length and detail confirm it is the actual prospectus, not just an announcement of a report.
2022-09-15 English
IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT 5 pages 309.3KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement detailing an $80 million institutional placement by Imugene Limited, including the terms of the share issue and options attached. It discusses the capital raising, share issuance, option terms, and the use of proceeds to fund clinical programs. There are no financial statements or detailed financial performance data included, nor is this a report or transcript. The content clearly relates to a capital raising event and financing update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive information about the financing event, not just a brief announcement or link to a report, so it is not an RPA or RNS.
2022-09-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.